<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471965</url>
  </required_header>
  <id_info>
    <org_study_id>OXALI_L_00858</org_study_id>
    <nct_id>NCT00471965</nct_id>
  </id_info>
  <brief_title>Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients</brief_title>
  <acronym>EACH</acronym>
  <official_title>Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary:&#xD;
&#xD;
        -  Overall Survival (OS)&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  Time to Tumor Progression (TTP)&#xD;
&#xD;
        -  Response Rate (RR)&#xD;
&#xD;
        -  Improvement of Quality of Life (QoL)&#xD;
&#xD;
        -  Safety&#xD;
&#xD;
        -  Secondary resection rate&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of randomization to the date of death due to any cause</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>From the date of randomization to documentation of progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate, secondary resection rate, quality of life</measure>
    <time_frame>From the date of randomization to the end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">371</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin + 5-Fluorouracil/Leucovorin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin + 5-Fluorouracil/Leucovorin</intervention_name>
    <description>Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.&#xD;
Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.&#xD;
Repeated every 2 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically, cytologically or clinically diagnosed (in patient with cirrhosis,&#xD;
             Alpha-Fetoprotein(AFP)≥400μg/L and morphological evidence [contrast Computed&#xD;
             Tomography(CT)/Magnetic Resonance Imaging(MRI)] of hypervascular liver tumor, elevated&#xD;
             AFP level due to other reasons [germ cell carcinoma, progressive chronic hepatitis,&#xD;
             pregnancy, etc] can be excluded) unresectable hepatocellular carcinoma, ineligible or&#xD;
             if the patient does not consent to receive local invasive treatment (chemo-embolism,&#xD;
             ablation, etc.).&#xD;
&#xD;
          -  At least one measurable lesion (on CT: ≥2cm, on spiral CT or MRI ≥1cm)&#xD;
&#xD;
          -  Have not received previous palliative systemic chemotherapy for metastatic disease. If&#xD;
             the patient received previous systemic chemotherapy as adjuvant treatment, he must&#xD;
             have been completed at least 12 months previously.&#xD;
&#xD;
          -  Patients progress after previous local treatment and at the time of randomization is&#xD;
             at least 4 weeks after the last interventional therapy (Hepatic Artery Infusion,&#xD;
             Trans-Artery Embolization or Trans-Artery Chemo-Embolization) or at least 8 weeks&#xD;
             after the last radiotherapy/ablation/ Percutaneous Ethanol Injection to the target&#xD;
             lesion.&#xD;
&#xD;
          -  Karnofsky Performance Score≥70, Barcelona of Cancer Liver Category stage B/C&#xD;
&#xD;
          -  Patients must have adequate organ and marrow function:&#xD;
&#xD;
               -  Neutrophilus≥1.5X10^9/L&#xD;
&#xD;
               -  Platelets≥75X10^9/L&#xD;
&#xD;
               -  Asparagine AminoTransferase,Alanine AminoTransferase&lt;2.5 Upper Normal Limit(UNL)&#xD;
&#xD;
               -  Total Bilirubin&lt;1.5 UNL&#xD;
&#xD;
               -  International Normalized Ratio&lt;1.5&#xD;
&#xD;
               -  Child stage A or B&#xD;
&#xD;
               -  Normal base line Left Ventricular Ejection Fraction (LVEF result must be above or&#xD;
                  equal to the lower limit of normal for the institution)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented allergy to platinum compound or to other study drugs.&#xD;
&#xD;
          -  Any previous oxaliplatin or doxorubicin treatment, except adjuvant treatment more than&#xD;
             12 months before the randomization.&#xD;
&#xD;
          -  Previous liver transplantation.&#xD;
&#xD;
          -  Patients concomitantly receiving any other anti-cancer therapy, including interferon-α&#xD;
             and herbal medicine which was approved by local authority to be used as &quot;anti-cancer&quot;&#xD;
             medicine, except radiotherapy to non-target lesion (bone metastasis, etc)&#xD;
&#xD;
          -  Patients who are receiving any other study treatments.&#xD;
&#xD;
          -  Pregnant or lactating women or women of childbearing potential without proper&#xD;
             contraceptive methods.&#xD;
&#xD;
          -  History of other malignant diseases, except cured basal cell carcinoma of skin and&#xD;
             cured carcinoma in-situ of uterine cervix.&#xD;
&#xD;
          -  Central nervous system metastasis&#xD;
&#xD;
          -  Other serious illness or medical conditions&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedict Blayney</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>May 9, 2007</study_first_submitted>
  <study_first_submitted_qc>May 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <last_update_submitted>September 17, 2010</last_update_submitted>
  <last_update_submitted_qc>September 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>Sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

